Guadecitabine + Atezolizumab combination
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-01-29 — Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed: Early-phase (Phase I/II) trial evaluating safety, optimal dosing, and efficacy of guadecitabine (next-gen HMA) plus atezolizumab (anti-PD-L1) in relapsed/refractory MDS or CMML, leveraging epigenetic-immunotherapy synergy. (novelty: 3)
Open questions
Related
Contributing findings
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
29-jan-2026
novelty 3
per-area 3
introduces